Drug Shortage Report for CISPLATIN INJECTION
Report ID | 131691 |
Drug Identification Number | 02403188 |
Brand name | CISPLATIN INJECTION |
Common or Proper name | CISPLATIN INJECTION 1MG/ML |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | CISPLATIN |
Strength(s) | 1.0MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 100ml |
ATC code | L01XA |
ATC description | OTHER ANTINEOPLASTIC AGENTS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2021-01-13 |
Estimated end date | 2021-05-31 |
Actual end date | 2021-05-05 |
Shortage status | Resolved |
Updated date | 2021-05-06 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2021-05-06 | French | Compare |
v5 | 2021-05-06 | English | Compare |
v4 | 2021-04-08 | French | Compare |
v3 | 2021-04-08 | English | Compare |
v2 | 2021-01-15 | French | Compare |
v1 | 2021-01-15 | English | Compare |
Showing 1 to 6 of 6